Describing the presence of anti-annexin V antibodies, cardiolipin and B2-glycoprotein 1 in females suffering recurrent pregnancy loss in Medellin, Colombia
DOI:
https://doi.org/10.18597/rcog.141Keywords:
Antibodies, antiphospholipid syndrome, antiphospholipid antibodies, anticardiolipin antibodies, annexin AV, recurrent abortionAbstract
Objective: Describing anti-annexin V antibody frequency in a series of females suffering recurrent abortion in Medellin.
Materials and methods: A series of cases was compiled, consisting of healthy females attending gynecological consultation who had a background of recurrent pregnancy loss (RPL), characterized by two or more abortions during the first three months of pregnancy. The females were attending a second- and third-level complexity healthcareproviding institution and/or private consultation with some gynecologists in Medellin who agreed to participate in the study. Females diagnosed with secondary antiphospholipid syndrome were excluded. Socio-demographic characteristics, obstetric and medical background emphasizing hypertension and thrombosis were evaluated, as were anti-cardiolipin antibodies, lupus anticoagulant, number of anti-β2-GPI antibodies and number of anti-annexin V antibodies. Such information was tabulated on a Microsoft Excel sheet and processed using Stata 10.0 statistical software; descriptive statistics were used for statistical analysis.
Results: 65 females were surveyed, their ages ranging from 18 to 46 years. Half the patients reported 2 abortions before the tenth week and the other half following such time. Anti-cardiolipin antibody results revealed that 4.6% (3) of the patients proved positive for IgM antibodies and 3.1% (2) positive for IgG antibodies. 3.1% (2) of the females had IgG and IgM anti-β2-GPI antibodies. 4.6% (3) of the patients were positive for anti-annexin IgG antibodies and 12.3% (8) had an indeterminate result.
Conclusions: Anti-annexin antibodies were detected in the patients surveyed in this study, although a subgroup of females had an indeterminate result. This led to advancing a hypothesis that annexin V could be an important and independent factor for cardiolipin and β2-GPI antibodies in recurrent pregnancy loss.
Author Biographies
María Victoria Mejía-Mejia
Angélica María Segura-Cardona
María Camila Velásquez-Escobar
María Camila Arango-White
Jazmín Abad-Restrepo
Martín Orrego-Vélez
Santiago Álvarez-Arango
Carlos Ignacio Uribe-Pardo
References
Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2008;90:S60.
Baek KH, Lee EJ, Kim YS. Recurrent pregnancy loss: the key potential mechanisms. Trends Mol Med 2007;13:310-7.
Ciarmatori S. Aborto recurrente de causa endocrina. Reproducción 2012;27:138-59.
Li TC, Makris M, Tomsu M, Tuckerman E, Laird S. Recurrent miscarriage: aetiology, management and prognosis. Hum Reprod Update 2002;8:463-81.
Anaya JM, Shoenfeld Y, Correa PA, Garcia-Carrasco M, Cervera R. Autoinmunidad y enfermedad autoinmune. 1a. ed. Medellin: CIB; 2005.
Bick RL. Antiphospholipid syndrome in pregnancy. Hematol Oncol Clin North Am 2008;22:107-20.
Speroff L, Glass RH, Kase NG. Recurrent early pregnancy loss. Clinical gynecologic endocrinology and infertility. 6a. ed. USA: Lippincott Williams and Wilkins; 1999.
Hanly JG, Smith SA. Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol 2000;120:537-43.
Mtiraoui N, Zammit W, Fekih M, Hider S, Mahjoub T. Lupus anticoagulant and antibodies to beta 2-glycoprotein I, annexin V, and cardiolipin as a cause of recurrent spontaneous abortion. Fertil Steril 2007;88:1458-61.
Wu XX, Arslan AA, Wein R, Reutelingsperger CP, Lockwood CJ, Kuczynski E, et al. Analysis of circulating annexin A5 parameters during pregnancy: absence of differences between women with recurrent spontaneous pregnancy losses and controls. Am J Obstet Gynecol 2006;195:971-8.
Rezk A, Abdel-Hafeez N, Rageh IM, Abdalla W. Anti-annexin as a marker in patients with recurrent miscarriages. Middle East Fertility Society Journal 2010;15:47-50.
Zammiti W, Mtiraoui N, Kallel C, Mercier E, Almawi WY, Mahjoub T. A case-control study on the association of idiopathic recurrent pregnancy loss with autoantibodies against beta2-glycoprotein I and annexin V, Reproduction 2006;131:817-22.
Tripathy NK, Sinha N, Nityanand S. Anti-annexin V antibodies in Takayasu's arteritis: prevalence and relationship with disease activity, Clin Exp Immunol 2003;134:360-4.
Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M. et al. Antiprothrombin and anti annexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases, J Rheumatol 2000;27:924-9.
Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipidantibody syndrome: a possible thrombogenic mechanism. N Engl J Med 1997;337:154-60.
Baleva MP, Histrova MH, Nikolov KV. Diagnostic significance of anti-annexin-A5 antibody determination. Cent Eur J Med 2010;5:6-11.
Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC, Wenstrom KD. Williams Obstetrics. 22 ed. New York: McGraw-Hill; 2005.
Ogawa H, Zhao D, Dlott JS, Cameron GS, Yamazaki M, Hata T, et al. Elevated anti-Annexin V Antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities. Am J Clin Pathol 2000;114:619-28.
De Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2- glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007;109:1490-4.
Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010:460-9.
Matsubayashi H, Arai T, Izumi S, Sugi T, McIntyre JA, Makino T. Anti-annexin V antibodies in patients with early pregnancy loss or implantation failures. Fertil Steril 2001;76:694-9.
EL-Gharib MN, Elhawary TM, Elshourbagy SH, Morad MA. Anti-annexin V Antibodies in Women with Recurrent Miscarriage. Clinical Medicine Insights: Reproductive Health 2010;4.
Bizzaro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R. Prevalence and clinical correlation of anti-phospholipid- binding protein antibodies in anti-cardiolipin negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 2005;129:61-8.
Suat K, Yavuz A, Fahri O, Aysenur B, Huriye B. Hereditary Thrombophilia, Anti-Beta2 Glycoprotein 1 IgM, and Anti-Annexin V Antibodies in Recurrent Pregnancy Loss. American Journal of Reproductive Immunology 2012;67:251-5.
Carp HJA. Antiphospholipid syndrome in pregnancy. Curr Opin Obstet Gynecol 2004;16:129-35.
Finazzi G. The Italian registry of Antiphospholipid antibodies. Haematologica 1997;82:101-5.
Passam F, Krilis S. Laboratory test Antiphospholipid syndrome:current concepts. Pathology 2004,36:129-38.
Baleva MP, Histrova MH, Nikolov KV. Diagnostic significance of anti-annexin-A5 antibody determination. Cent Eur J Med 2010;5:6-11.
Alijotas-Reig J, Ferrer-Oliveras R, Rodrigo-Anoro MJ, Farran-Codina I, Llurba-Olive´ E, Vilardell- Tarres M, et al. Antiannexin A5 antibodies in women with spontaneous pregnancy loss. Med Clin (Barc) 2010;134:433-8.
Arnol J, Holmes Z, Pickering W, Farmer C, Regan L, Cohen H. Anti-B2GPI y anti-annexin V antibodies in women with recurrent miscarriage. Br J Haematology 2001;113:911-4.
Bizzaro N, Antico A, Musso M, Platzgummer S, Camogliano L, Tozzoli R, et al. A prospective study of 1038 pregnancies on the predictive value of antiannexin V antibodies for foetal loss. Ann NY Acad Sci 2005;1050:348-56.
How to Cite
Downloads
Downloads
Published
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
